Business Wire

New Data Show Statistically Greater Improvements in Clinical Outcomes with Subcutaneous Infliximab, Compared to Intravenous Infliximab, in Patients With Rheumatoid Arthritis


A new post-hoc analysis of a pivotal phase III randomised controlled clinical trial shows that the subcutaneous (SC) formulation of infliximab, Remsima® (CT-P13), is associated with significantly greater improvements in clinical outcomes compared to the intravenous (IV) formulation of infliximab at week 30, in patients with rheumatoid arthritis (RA). Between-group (SC vs. IV) differences were reduced at week 54, suggesting improved responses after switching from IV to SC infliximab.1 The data were presented today at the Annual European Congress of Rheumatology (EULAR 2022).

“It’s important for people living with rheumatoid arthritis to effectively control their disease, and when there are signs one’s RA treatment is not working as well as it used to, one might need to consider re-evaluating the treatment strategy. Today, many medications have changed the treatment landscape of rheumatology, allowing low disease activity and remission to be achieved in people with RA,” said Professor Arnaud Constantin, Rheumatologist at Rheumatology Department, Purpan University Hospital and Toulouse III – Paul Sabatier University, Toulouse, France. “Switching to medications such as the SC formulation of infliximab could allow patients to have better control of their treatment and improved quality of life.”

The post-hoc study investigated whether the numerical advantage of SC infliximab compared to IV, shown in most efficacy parameters at weeks 30 and 54, was statistically significant. This was achieved using conservative imputation methods, such as non-responder imputation (NRI) and last observation carried forward (LOCF), in 343 patients who were randomised at week six into two treatment arms (165 patients received SC 120mg bi-weekly and 174 patients received IV 3mg/kg every 8 weeks).

Results showed a statistically significant difference in favour of SC compared to IV-treated patients at week 30 in almost all clinical variables, including low disease activity rates and remission rate. In addition, after switching at week 30 to SC infliximab, the proportion of RA patients achieving either low disease activity rates or a ‘good response’, as measured by EULAR CRP, was increased at week 54, suggesting improved responses after switching from IV to SC.

“The results presented today at EULAR provide further evidence to the efficacy of SC infliximab, as switching from IV to SC infliximab was associated with improvements in clinical response. The positive outcomes following switching from IV to SC infliximab provide reassurance to patients and the healthcare professionals who treat them,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare.

- ENDS -

Notes to Editors:

About rheumatoid arthritis2,3,4,5

Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes pain, swelling and stiffness in joints. Approximately 1% of the population worldwide suffer from RA, however, the cause of it remains unknown. Symptoms of RA develop due to a faulty immune system that attacks healthy cells, but it is currently unknown why the immune system behaves in this way. Although there's no cure for rheumatoid arthritis, early treatment such as disease-modifying anti-rheumatic drugs (DMARDs) and biological treatments can reduce the risk of joint damage and limit the impact of the condition.

About CT-P13 (biosimilar infliximab)

CT-P13 is developed and manufactured by Celltrion, Inc. and was the world’s first monoclonal antibody biosimilar approved by the European Commission (EC). It is indicated for the treatment of eight autoimmune diseases including Rheumatoid Arthritis (RA) and Inflammatory Bowel Disease (IBD). It was approved by the EC under the trade name Remsima® in September 2013 and launched in major EU countries in early 2015. The US Food and Drug Administration (FDA) approved CT-P13 in April 2016 under the trade name Inflectra®. CT-P13 is approved in more than 98 countries (as of May 2022) including the US, Canada, Japan and throughout Europe.

About Remsima® intravenous (IV) formulation6

Remsima® IV is usually given as 3 mg per kg/body weight in rheumatoid arthritis (RA) and as 5 mg per kg/body weight for the other indications including IBD. Infliximab IV is given as an infusion over two hours. All patients are monitored for any reactions during the infusion and for at least one to two hours afterwards.

About Remsima® subcutaneous (SC) formulation

A 120 mg fixed dose of Remsima® SC has been granted marketing authorisation in the EU, in adults regardless of body weight, in all previously approved indications in adult for the IV formulation. Remsima® SC has three available devices; via a pre-filled pen (auto injector), pre-filled syringe or pre-filled syringe with needle safeguard.6 The SC formulation has the potential to enhance treatment options for the use of infliximab by providing high consistency in drug exposure and a convenient method of administration.7,8

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA Current Good Manufacturing Practice (cGMP) and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information, please visit:


1 Arnaud Constantin, et al. Efficacy of Subcutaneous Infliximab (CT-P13 SC) Compared with Intravenous Infliximab in Rheumatoid Arthritis: A Post-hoc Analysis of a Phase 3 Randomized Controlled Trial.

2 Arthritis Research UK. Rheumatoid arthritis. Available at [Last accessed as of May 2022]

3 Allan Gibofsky. Overview of Epidemiology, Pathophysiology, and Diagnosis of Rheumatoid Arthritis. American Journal of Managed Care. 2012;18:S295-302.

4 Arthritis Foundation. Rheumatoid Arthritis. Available at [Last accessed as of May 2022].

5 NHS UK. Treatment Available at [Last accessed as of May 2022]

6 European Medicines Agency Summary of Product Characteristics (SmPC). Infliximab. Available at [Last accessed as of May 2022].

7 Yoo DH, Jaworski J, Matyska-Piekarska E et al. A Novel Formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: One-year results from part one of a Phase I/III randomised controlled trial in patients with rheumatoid arthritis. Poster (FRI0128). Presented at EULAR 2019.

8 Westhovens R, Wiland P, Zawadzki M et al. A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 30-week results from part two of a Phase I/III randomised controlled trial in patients with rheumatoid arthritis. Poster (SAT0170). Presented at EULAR 2019.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Holly Barber
+44 (0) 7759 301620

Donna Curran
+44 (0) 7984 550312

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NelsonHall Highlights the Strength of Mercans’ Global Employer of Record Services30.6.2022 16:00:00 CEST | Press release

“We are delighted that NelsonHall, the leading global analyst firm, has recognized Mercans as one of the fastest growing technology-driven global employer of record service providers. NelsonHall’s analyst report is a testament to the success of our EOR service line and demonstrates that our proprietary technology, combined with Mercans’ local presence in 160 countries, creates value for our customers and their employees,” said Tatjana Domovits, Group CEO of Mercans. This press release features multimedia. View the full release here: Salman Saeed - Head of EOR - Mercans (Photo: AETOSWire) Mercans’ global employer of record services delivery model is unique in the industry and focuses on the excellence in customer and employee experience through digitalization, employee-centric support, and in-country expertise. Mercans has invested significantly in developing a proprietary global payroll software, HR Blizz™ with 160 country cover

IBS Intelligence Recognizes Temenos as the #1 Best-Selling Banking Software in Six Categories; the Highest Awarded to Any Technology Provider30.6.2022 15:42:00 CEST | Press release

Temenos (SIX: TEMN) has been recognized as the market's leading open platform for composable banking in the IBS Intelligence Sales League Table (SLT). IBSi recognized Temenos as the leader in six categories, more than any other technology provider, including digital banking and channels, core banking and payments. The IBSi SLT 2022 assessed systems purchases made by over 1000+ banks across 250+ products from 60 suppliers. Temenos was ranked: #1 best-selling Universal Banking - Core Banking solution with 49 new named deals, maintaining its market leadership with 49% of total deals in the market. Temenos was the only major core vendor to increase its market share year-on-year #1 for Digital Banking and Channels – signing 79 deals, maintaining more than 50% market share in the Americas #1 in Payments Systems for retail banking, for the fourth consecutive year, with 43 new named deals #1 for Risk Management with 39 new name deals, 2X the number of deals of the next vendor #1 for Islamic Co

SES Appoints Kyle Pilkington as Chief Legal Officer30.6.2022 15:15:00 CEST | Press release

SES AI Corporation (NYSE: SES), a global leader in the development and manufacturing of high-performance lithium-metal (Li-Metal) rechargeable batteries for electric vehicles (EVs) and other applications, today announced the appointment of Kyle Pilkington to the position of Chief Legal Officer, effective July 1, 2022. Pilkington, who was previously VP, Legal, is based in the United States and replaces Joanne Ban on the company’s Executive Team. Ban is retiring from the position due to health reasons but will continue to serve SES as an advisor to the CEO. SES Founder & CEO, Qichao Hu said: “I am pleased to welcome Kyle to SES’s Executive Team. He brings a wealth of global experience particularly in securities laws matters and the effective oversight of legal, governance and regulatory matters and will play a key role working with me, our Board and the rest of our team as we continue to grow and strengthen the company. We also thank Joanne for all the valuable contributions over the pas

Sevan Ranked Among Top Firms on Engineering News-Record’s Lists for Fifth Consecutive Year30.6.2022 15:00:00 CEST | Press release

Sevan Multi-Site Solutions, Inc. (Sevan) has earned spots on lists published by Engineering News-Record (ENR) for the fifth consecutive year. Sevan, a global leader in innovative program management for clients with multiple sites, was ranked No. 36 on ENR’s Top 50 Program Management Firms and No. 57 on the Top 100 Construction Management-for-Fee Firms. “Our placement on the ENR lists is a result of the extraordinary commitment our team members have to delivering excellence for our clients and business partners,” said Jim Evans, Founder and CEO of Sevan. “We are honored to be listed alongside other industry leaders on this esteemed list. Congratulations to all!” The lists recognize firms finding new momentum in their business, and rankings are based on annual revenue. ENR conducts annual surveys that assess key segments of the construction industry and ranks companies within those areas. In 2022, Sevan was recognized as an Employee-Rated Great Place to Work® for the 9th consecutive year

Affinity Appoints Two Key Executives from Robinhood and Showpad30.6.2022 15:00:00 CEST | Press release

Affinity, the relationship intelligence platform for dealmakers, today announced the appointments of two key executives: Dustin Deno as Chief Revenue Officer (CRO) and Rich Bessel as Vice President of Design. “Over the past few years, we’ve seen exponential growth across relationship-driven industries,” said Ray Zhou, co-CEO and co-founder at Affinity. “As we enter our next stage of growth we are excited to welcome Dustin and Rich to our executive team. Their strong track records of driving revenue growth and designing world-class products at leading technology companies will be critical as we scale to meet growing market demand.” Deno brings over 15 years of experience in SaaS, including building and scaling sales teams at Salesforce and Showpad. While at Showpad, Deno helped to grow global sales teams after the company secured their Series D funding and successfully navigated the team through the pandemic. Deno will lead Affinity’s world-class velocity sales organization and prepare

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom